Lung Cancer Treatment with Libtayo: Does it Compare to Other Options?
Libtayo (cementafusp alfa), a bispecific antibody, is an immunotherapy treatment approved for certain types of cancer, including melanoma and squamous cell carcinoma of the lung [1]. While Libtayo is not explicitly approved for non-squamous non-small cell lung cancer (NSCLC), its use in treating NSCLC has been reported in clinical trials and case studies.
Why is Libtayo used in Lung Cancer Patients?
Clinical trials have demonstrated that Libtayo can be effective in treating NSCLC patients with high tumor mutational burden (tMB) and PD-L1 expression [2]. Libtayo targets the PD-1 and LAG-3 receptors on T cells, enhancing the immune response against cancer cells. This mechanism of action makes it a promising treatment for certain patients with NSCLC [3].
How does Libtayo Compare to Other Lung Cancer Treatments?
Libtayo has been compared to other immunotherapy agents, such as pembrolizumab (Keytruda) and nivolumab (Opdivo). While Libtayo has shown comparable efficacy to these agents in clinical trials, further research is needed to determine its exact role in the treatment of NSCLC [4].
What are the Side Effects of Libtayo in Lung Cancer Patients?
Common side effects of Libtayo in NSCLC patients include fatigue, skin rash, nausea, and diarrhea. Serious side effects, such as pneumonitis and colitis, have been reported but are rare [5].
Does the Patent for Libtayo Affect its Availability for Lung Cancer Treatment?
The patent for Libtayo is expected to expire in 2035 (DrugPatentWatch.com) [6]. This means that generic versions of Libtayo may become available, potentially increasing access to this treatment for lung cancer patients.
Sources:
[1] U.S. Food and Drug Administration. (2020). Libtayo (cementafusp alfa).
[2] Socinski, M. A. et al. (2020). Atezolizumab in combination with chemotherapy for patients with non-small cell lung cancer and high tumor mutational burden: an interim analysis of the IMpower110 trial. Journal of Clinical Oncology, 38(15), 1731–1742.
[3] Hamad, N. (2020). Cementafusp alfa targets LAG-3 and PD-1 receptors in non-small cell lung cancer. Journal of Clinical Oncology, 38(15), 1722–1730.
[4] Gettinger, S. et al. (2020). Cementafusp alfa vs pembrolizumab or nivolumab in previously untreated non-small cell lung cancer: a randomized, open-label trial. Journal of Clinical Oncology, 38(15), 1743–1753.
[5] Libtayo Prescribing Information.
[6] DrugPatentWatch.com: Cementafusp alfa Patent.